KNOWLEDGE BANK

Interviews

Peering into the Future

Co-founder and CTO, BrainSightAI
Dr Rimjhim Agrawal Cofounder and CTO of BrainSightAI has expertise in neuroscience and machine learning to solve complex challenges in this field Her PhD in psychiatry coupled with a strong focus on AI in neuroscience drove early research into utilising AI to gain deeper insights into complex psychiatric disorders such as schizophrenia and OCD Her research has resulted in significant contributions...

Articles

From Gene Editing to Network Medicine

Biomedicine is undergoing a profound transformation driven by the convergence of genomics artificial intelligence and systems biology Traditional drug discovery largely focused on identifying a single molecular target and designing a compound capable of modulating that target While this strategy has produced many successful medicines it often struggles to address complex diseases such as cancer me...

Research Insights

mRNA and circRNA Mislocalization to Synapses are Key Features of Alzheimer’s Disease

Proper transport of RNAs to synapses is essential for localized translation of proteins in response to synaptic signals and synaptic plasticity Alzheimers disease AD is a neurodegenerative disease characterized by accumulation of amyloid aggregates and hyperphosphorylated tau neurofibrillary tangles followed by widespread synapse loss To understand

Case Studies

An Observational Case Study Of Prescription Patterns Of Antibiotics In Treating Lower Respiratory Tract Infections

Abstract Antibiotics are of the oldest discovered drugs that combat specific micro organisms like bacteria and fungi Although there are several classification schemes for antibiotics based on bacterial spectrum broad vs narrow or route of administration injectable vs oral vs topical or type of activity bactericidal vs bacteriostatic the most usefu

Techno Trends

India Strengthens Regulatory Framework for Clinical Trials Following Recent FDA Guidelines

India enhances its clinical trial regulations to align with updated FDA guidelines promoting global research collaboration

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Machine Learning for New Drugs

Sneha Rai

Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.

 

Venugopal Bhatia

Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.

 

Sonika Bhatnagar

Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.

 

2

Role of Nutraceutical in Various Diseases - A Review

Shaikh Habeeba

Shaikh Habeeba working as an assistant professor at matoshri institute of pharmacy dhanore yeola nashik Maharashtra India. She has completed post-graduation in pharmacognosy. Her area of research interest in herbal formulation development. She has published more than 20 research& review paper in various national international journal. One case study accepted as book chapter in international publication & attended 17 conference &  presented 5 paper in international national  conference also guided  more than 5 students for the research project.

 

3

Demystifying Lead-time bias and Length-time bias in Clinical Trials

Jefry Winner G

Jefry Winner G has completed his MBBS from Vinayaka Missions Medical College. He is currently pursuing a Doctorate of Medicine in Pharmacology at JIPMER Puducherry. He is interested in clinical research and is currently involved in an academic clinical trial involving Epilepsy. He has four years of clinical experience in healthcare and Academia. His area of interest includes Clinical trials, Pharmacotherapeutics, Drug safety, and clinical pharmacology. He also has over 15 publications in peer-reviewed journals.

 

4

Pharma Regulatory Bottlenecks and Vaccination Delays

Sonam Chandwani

Sonam Chandwani is the Managing Partner at KS Legal & Associates. Her experience encompasses commercial and crosses border transactions across various sectors, advising both Indian companies in their outbound investments and foreign companies investing in India, on diverse areas of Indian laws concerning Mergers & Acquisitions, Insolvency & Bankruptcy, Banking & Finance, Real Estate, Arbitration and Litigation in Courts and Tribunals on a PAN-India basis.

 

5

Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis

Sindhoor S M

Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.

 

Marina Koland

Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.

 

press releasesRead more...

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix Pharmaceuticals Limited ASX TLX NASDAQ TLX Telix today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE ITM a global leader

BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

Boomray Pharmaceuticals Co Ltd BoomRay a clinicalstage biotechnology company pioneering innovative radioligand therapies RLTs for precision oncology diagnostics and therapeutics

Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NewAmsterdam Pharma Company NV Nasdaq NAMS or NewAmsterdam or the Company a latestage clinical biopharmaceutical company developing oral nonstatin medicines for patients at risk

University of Sydney launches Australia's new ace against cancer

An Australianfirst cancer research facility that will allow scientists to examine individual cancer and immune cells in unprecedented detail has officially opened at the University of Sydney marking

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Tempus AI Inc NASDAQ TEM today announced an extension of its data license agreement with Recursion Pharmaceuticals Inc NASDAQ RXRX Additionally the two companies have entered

WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion

WuXi XDC Cayman Inc a leading global Contract Research Development and Manufacturing Organization CRDMO focused on the bioconjugate industry today held a grand GMP release ceremony

EventsRead more...

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

29 - 01

Sep 2026

10th IPF Summit 2026

Boston, MA, USA

29 - 01

Sep 2026

Powtech Technopharm 2026

Nuremberg, Germany

30 - 01

Sep 2026

Pharma Launch Excellence Summit

Hyatt Regency Boston Harbor, B...

LATEST NEWSRead more...

Merck’s KEYTRUDA QLEX Approved for Subcutaneous Administration

Merck has announced that Japans Ministry of Health Labour and Welfare MHLW has approved KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfapmph for subcutaneous administration

Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody BsAb therapies for immunology and inflammation II diseases

Eisai and Biogen Receive Approval for LEQEMBI Pen for Early Alzheimer’s Disease

Eisai and Biogen have received approval in Japan for LEQEMBI Pen a subcutaneous SC formulation of lecanemab for the treatment of early Alzheimers disease AD

QurCan Therapeutics Enters into Collaboration with Lilly Advance Nucleic Acid Therapies for Nervous System Diseases

QurCan Therapeutics has entered into an exclusive research and collaboration agreement with Eli Lilly and Company to develop nucleic acid therapies for diseases affecting the central nervous system CNS and peripheral nervous system PNS

BostonGene Expands Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene has expanded its scientific collaboration with DanaFarber Cancer Institute to study the biological mechanisms involved in breast cancers associated with BRCA and BRCA mutations

Telix Receives Approval for Pixclara for Brain Cancer Imaging

Telix Pharmaceuticals has received approval from the US Food and Drug Administration FDA for Pixclara floretyrosine F or FFET a radioactive diagnostic drug used with positron emission tomography PET to image gliomas a type of brain cancer